[{"orgOrder":0,"company":"Juniper Biologics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Juniper Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Juniper Biologics \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Juniper Biologics \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Helsinn Advanced Synthesis \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Kyowa Kirin"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Centre for Human Drug Research \/ Recordati Rare Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Recordati Rare Diseases"}]

Find Clinical Drug Pipeline Developments & Deals for Mechlorethamine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : VALCHLOR® (mechlorethamine) gel 0.016% is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy.

                          Product Name : Ledaga

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 18, 2022

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day.

                          Product Name : Ledaga

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 21, 2022

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 31, 2022

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Recordati Rare Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.

                          Product Name : Ledaga

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 09, 2022

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Helsinn Advanced Synthesis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR® in China. Helsinn will be responsible for clinical development, regulatory activities, and the supply of VALCHLOR® for commercial use in China.

                          Product Name : Ledaga

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 12, 2020

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Kyowa Kirin

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2018

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Rochester Skin Lymphoma Medical Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Rochester Skin Lymphoma Medical Group

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 20, 2017

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Rochester General Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Sidney Kimmel Cancer Center, Thomas Jefferson University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Sidney Kimmel Cancer Center, Thomas Jefferson University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 20, 2017

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Thomas Jefferson University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Thomas Jefferson University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 29, 2016

                          Lead Product(s) : Mechlorethamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank